Lab-grade blood testing from the comfort of your home.
We are actively seeking strategic partnerships with venture capital and biotech accelerators to build our initial MVP and unlock the full potential of biomolecule AI.
Contact Us ↗
SCRY BIO
Scry bio is building at-home blood tests which deliver results within the first hour of use. Our tests allow users to prick their finger on a disposable device, and get health insights from a visible colour readout.
Starting with lung cancer screening, we're building truly equipment-free diagnostics that will make early detection accessible to everyone. Imagine the convenience of a COVID-19 rapid test, but for every life-threatening disease.
We're changing the paradigm of healthcare, one test at a time.
Meet the team ↗
OUR science
Protected by a highly differentiated patent position, PULSE siRNA™ therapies have the requisite drug profile to treat life-threatening areas of clinical unmet need, where a short duration of target gene silencing is mission critical.
Pulse RNA platform:
OUR science
At SCRY bio, we are developing the first electricity-free artificial intelligence platform built from DNA circuits.
Our molecular computers execute machine learning algorithms directly in biological samples, detecting proteins, mRNA, and small molecules while computing complex non-linear relationships between biomarkers. Unlike electronic computers, our computers can interface directly with blood samples, compute without electricity, and can be thrown out after use.
SCRY biomolecule AI platform:
OUR TEAM
Our team at SCRY bio consists primarily of research scientists with broad technical expertise in AI, immunoengineering, microfluidics, and DNA nanotechnology. In the past, we held positions at the Ontario Medical Association, Mt. Sinai Hospital, Brigham and Women's Hospital, as well as entrepreneurial roles in various local businesses.
We have a panel of consulted experts consisting of scientists, physicians, economists, and policy makers. Together, we share a mission to make healthcare screening simple and convenient for patients.
Farshad is a PhD Candidate in Biomedical Engineering at the University of Toronto, where he pushes the limits of biomarker detection using DNA nanotechnology. He designs cost-effective nanotech platforms for immune cell diagnostics, multimeric T-cell reagents to identify rare immune cells, and nanocarriers for therapeutics.
He holds an undergraduate degree in Health Sciences and Biology from Western University, where he studied carbohydrate-based cancer vaccines. During his time with the Ontario Medical Association’s Economics and Policy divison, he promoted physician safety during the COVID-19 pandemic. He also published a study using novel case-mix methodologies to track chronic disease and multimorbidity trends across Ontario, revealing shifting burdens in healthcare resource allocation.
Today, he leads the SCRY bio team as CEO and co-founder, where he is pioneering electricity-free molecular computers to bring healthcare screening to the masses at home.
LinkedIn
Eric's doctoral research focuses on understanding biological responses to DNA-based materials, which is crucial for the translation of DNA-based technologies to clinical applications such as disease screening and diagnostics. He also investigates how DNA modifications could be used to direct biological responses.
Eric received his B.A.Sc. from the University of Toronto, where he studied Biomedical Systems Engineering. During his research position at the Brigham and Women's Hospital and Harvard University, he developed a polymeric microneedle patch for sampling interstitial biomarkers to monitor dermal autoimmune disease. Beyond microneedles, Eric and his team invented "surgery in a pill", now the product of AltrixBio, which has received 9.9M USD in funding to date.
As COO of SCRY bio, Eric's holistic view on the interface between materials and biology ensures SCRY bio's blood tests find a place in your medicine cabinet at home.
LinkedIn ↗
Ryan received his B.Sc in Biology & Psychology from McMaster University, and is currently defending his doctoral thesis at the department of Biomedical Engineering in University of Toronto. He has spent the past 6 years developing the foundation for SCRY bio's DNA AI, a biomolecule "software package" to quickly build, test, and prototype different AI models in a test tube.
In addition to his expertise in molecular computing, he designed and fabricated multilayer microfluidics at the Institute of Quantitative Biology, Biochemistry, and Biotechnology at the University of Edinburgh, Scotland, UK. These designs house and control the flow of the complex biochemical reactions which make up our DNA AI.
When Ryan is not building as the CTO of SCRY bio, he spends his free time building custom ergonomic electronics, prototyping and racing quadcopters, and playing the electric guitar.
LinkedIn ↗
"CatSci's purpose is to get new medicines into the hands of patients in need and partnering the game changing siRNA drug development potential at Argonaute is a collaboration we are very excited about. Together we are exploring solutions for the manufacture of high-quality siRNA drug substance to enable robust preclinical studies and at scale for clinical trials."
- Dr Ross Burn (CEO, CatSci)
“Our businesses interact seamlessly to ensure IP generation and business objectives are robust, enforceable and value generating.”
- Rob Docherty PhD EPA MBA (Director, Symbiosis IP)
“At Carbometrics we specialise in the synthesis and bioconjugation of synthetic molecular recognition agents. Our collaboration with Argonaute is an excellent fusion of competencies and an exciting opportunity for us to use our chemistry expertise to augment what is already a paradigm shifting siRNA platform to create revolutionary therapeutics”
- Andy Chapman (CEO and Co-founder, Carbometrics)
